Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Switzerland
/
Pharmaceuticals & Biotech
/
Cosmo Pharmaceuticals
COPN
Cosmo Pharmaceuticals
EMA Hurdles And Generics Will Stall Growth But Enable Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
04 Aug 25
Updated
10 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
CHF 78.65
28.8% undervalued
intrinsic discount
10 Aug
CHF 56.00
Loading
1Y
-26.7%
7D
0.2%
Author's Valuation
CHF 78.6
28.8% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
CHF 78.6
28.8% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-31m
234m
2014
2017
2020
2023
2025
2026
2028
Revenue €187.2m
Earnings €65.2m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
21.96%
Pharma revenue growth rate
1.01%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
4.53%
Calculation
€65.20m
Earnings '28
x
21.96x
PE Ratio '28
=
€1.43b
Market Cap '28
€1.43b
Market Cap '28
/
15.62m
No. shares '28
=
€91.66
Share Price '28
€91.66
Share Price '28
Discounted to 2025 @ 4.53% p.a.
=
€80.25
Fair Value '25
€80.25
Fair Value '25
Converted to CHF @ 0.9410 EUR/CHF Exchange Rate
=
CHF 75.52
Fair Value '25
